Biotech stock Halozyme Therapeutics is climbing back in constructive form from a severe drop in November. Shares got a boost after the drug-delivery developer reiterated its 2024 forecast and raised ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback